Individualized treatment of symptoms and exocrine and endocrine insufficiency is necessary, because patients have variable expression of disease. Finally, ongoing monitoring provides opportunities to detect complications at earlier stages so that more effective therapy is possible. Optimal management of these patients requires a multidisciplinary team that includes gastroenterologists, surgeons, endocrinologists, dieticians, pain management, psychiatrists, social workers, and patient support groups.
Diagnostics
Chronic pancreatitis is usually diagnosed based on results of imaging analyses or tests of pancreatic function. Although histologic evidence of fibrosis and tissue loss might be considered the most definitive diagnostic criteria, it is rarely available.
In addition, similar changes in histologic features are observed in patients without symptoms of chronic pancreatitis, such as very elderly patients, those with diabetes or renal failure, and those who smoke. These changes can result from normal "wear and tear" on the pancreas. Diagnosis requires recognition of the variety of symptoms (if present) and complications that constitute the syndrome [3] , in conjunction with appropriate imaging or functional tests (Table 1 ). In early stages of disease progression, results from these tests can be negative or inconclusive. In later stages, marked changes in pancreatic structure and function make diagnosis much easier and more accurate. Of course, at this later stage, there is less opportunity to interrupt disease progression.
Table 1

Diagnostic Tests for Chronic Pancreatitis
Accurate diagnosis is therefore especially important during the early stages of disease. Patients arrive at many pancreas specialty clinics with a chronic abdominal pain syndrome and normal results from pancreatic imaging tests, yet they have been incorrectly diagnosed with chronic pancreatitis and may have been subjected to dangerous and ultimately futile interventions, such as endoscopic retrograde cholangiopancreatography (ERCP) with stent placement or prescriptions for narcotics.
Characteristic findings from imaging techniques such as computed tomography (CT) or ultrasonography include atrophy of the pancreas, a dilated pancreatic duct, and pancreatic calcifications (Fig. 1) . These features are pathognomonic of chronic pancreatitis and can take 5 to 10 years or more to develop [1] . Pancreatic calcifications seem to be much more common in patients with certain forms of chronic pancreatitis, especially those with hereditary pancreatitis (caused by variants of PRSS1), patients who smoke or drink alcohol, or patients with tropical pancreatitis.
Patients with chronic pancreatitis of other etiologies can also develop calcifications, detected by imaging tests, although these are observed less frequently and develop more slowly. Additional methods to image the pancreas include magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP, with or without the secretagogue secretin), endoscopic ultrasonography (EUS), and ERCP. MRI with MRCP has replaced CT at many institutions. One advantage of MRI is that it can be used to characterize the pancreatic ductal anatomy (with MRCP), but it often misses calcifications. Administration of secretin during MRCP improves the quality of images of the pancreatic duct, although the gain in diagnostic accuracy with this technique has not been defined. In addition, the quantity of pancreatic secretions can be estimated using MRI with secretin [4] .
EUS allows for detailed imaging of the pancreatic duct and parenchyma (Fig.   2 ). EUS images can be interpreted using the traditional 9-feature scheme or the newly proposed Rosemont criteria [5] . These systems do not appear to differ in diagnostic accuracy for chronic pancreatitis. However, it is important to recognize that subtle abnormalities detected by EUS are nonspecific and not sufficient for diagnosis of chronic pancreatitis. EUS has a high level of sensitivity and a low level of specificity. Fig. 2 . EUS image shows subtle sonographic features of chronic pancreatitis, with a hyperechoic duct margin and hyperechoic foci in the gland. These features are nonspecific and cannot be used alone to diagnose chronic pancreatitis.
Imaging techniques such as CT, MRI, and EUS can also be used to exclude other conditions that produce similar symptoms to, or complicate, chronic pancreatitis, especially pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm, and other cystic neoplasms. Although ERCP provides detailed images of the pancreatic duct, it is not appropriate for use in diagnosis of chronic pancreatitis, although it might be used therapeutically. Fig. 1 ).
Analysis of the fluid collected during a direct pancreatic function test, in addition to bicarbonate concentration, can allow additional insights into mechanisms of disease and identify new diagnostic tools. Differentially expressed proteins can be identified in pancreatic secretions from patients with chronic pancreatitis compared with patients with nonpancreatic pain [7] . These proteins include many involved in inflammation, fibrosis, and pain. Similar analyses are possible in patients with malignant or premalignant pancreatic disease. Whether these approaches will evolve to accurate diagnostic tests in early chronic pancreatitis is not yet known.
Determination of Etiology
In the past, alcohol consumption was believed to cause most cases of chronic Physicians should make vigorous efforts to encourage sustained abstinence for patients with chronic pancreatitis as early in the clinical course of disease as possible.
A randomized trial showed that even simple interventions (a 30-minute discussion), delivered in a repeated and systematic way, helped patients abstain from alcohol and reduced recurrence of pancreatitis [9] . Because many gastroenterologists may not have the expertise or experience to provide support for smoking cessation and alcohol abstinence, referral of patients to appropriate support groups should be consistently provided.
Treatment of Pain
Most patients with chronic pancreatitis have abdominal pain. Pain takes many forms; a common presentation is a chronic and continuous pain, with or without exacerbations. Pain severity, character, timing, and response to therapy vary. Pain can change over time in individual patients and in some patients can eventually disappear. Pain can develop during early stages of chronic pancreatitis, before development of easily visible structural abnormalities of the pancreas. In this situation, it can be difficult to determine if pain is actually caused by chronic pancreatitis. Pain is the symptom that most frequently causes patients to seek medical care; it accounts for most chronic pancreatitis-associated medical costs and causes the greatest reductions in social function and quality of life. Recent studies have found that certain pain patterns are most detrimental to quality of life. Continuous pain, even if less intense than intermittent pain, is associated with a lower quality of life, increased disability, and greater health care utilization [10] . It is helpful to quantify pain severity and character, determine baseline levels of pain, and measure the effects of therapies. Some assessment of quality of life and disability is also appropriate on a periodic basis.
In the past, pain was believed to be mainly caused by obstruction of the pancreatic duct (by stricture or stone), which results in high pressure or ischemia above the obstruction. Therapies that relieve the obstruction, such as ERCP with stent placement or surgical ductal drainage, were therefore used to treat pain.
Although this approach has been successful in some patients, its effects are There are significant changes in brain function, microstructure, and macrostructure in patients with painful chronic pancreatitis, producing changes in electroencephalography patterns, brain-evoked potentials, and cortical organization and thickness. These changes are similar to those observed in patients with other conditions that cause chronic visceral or somatic pain. These changes in nociception indicate that pancreatitis-related pain could be primarily a "wiring" problem, rather than a plumbing problem, that would not respond to treatments that simply remove ductal obstructions [11] . These changes could account for the benefits of agents such as gabapentoids in reducing pain in patients with chronic pancreatitis [12] . Their effects are likely to result from their abilities to modulate nociception. Finally, it is worth noting that the placebo response in these patients is at least 20%.
The first step in treating pain is to search for treatable complications of chronic pancreatitis. These could include a pancreatic pseudocyst, obstruction of a surrounding hollow viscus (bile duct or duodenum), or cancer. Although these complications do not always cause pain, they do have specific treatments. Cross-sectional imaging with CT or MRI can be used to identify complications and screen for conditions that produce symptoms that are similar to those of chronic pancreatitis (pancreatic adenocarcinoma or intraductal papillary mucinous neoplasm).
Pain treatment begins with medical therapy. One important goal of effective medical therapy is to slow disease progression, which involves focused efforts to achieve abstinence from tobacco and alcohol if they have roles in disease development. Alcohol abstinence usually reduces pain, although the magnitude of the effect is unpredictable. More importantly, abstinence slows disease progression, reduces the likelihood of complications such as carcinomas, and prolongs life [13] .
Most patients with pain will require analgesics. Cross-sectional and cohort studies estimate that approximately half of all patients with chronic pancreatitis will be treated with opioids. The precise risk of addiction is not known, but studies of patients with other chronic pain syndromes indicate that it is less than 20%. Patients with previous addictive behaviors, including alcohol abuse or smoking, are most prone to dependence, abuse, or addiction; the rate of addiction and other aberrant drug-related behaviors thus varies among patients with chronic pancreatitis.
Notwithstanding the risk of addiction, the main goal is pain relief. It is appropriate to begin treatment with less-potent opioids. Tramadol is commonly used for this purpose in dosages of 200 to 400 mg daily, although higher dosages are given to some patients. More potent narcotics are often required, and it is appropriate to slowly increase potency and frequency, with a goal of reducing but not eliminating pain. A number of other agents are given with opioids to manage chronic pain syndromes. These include tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and gabapentoids. Of these, only pregabalin has been studied in a randomized controlled trial in patients with chronic pancreatitis [12] . Patients treated with pregabalin (up to 300 mg twice daily)
had reduced pain compared with those given placebo and were able to reduce opioid use. Side effects were more common in the pregabalin group (lightheadedness or a feeling of being drunk). Preliminary studies suggest that pregabalin inhibits central sensitization. It is not clear whether other adjunct agents are equally effective or if combinations of these agents are more effective. Nonetheless, use of adjuvant agents is reasonable for patients who require opioids for pain control.
Additional medical options for pain include administration of pancreatic enzymes, octreotide, antioxidants, and various nontraditional therapies. Pancreatic enzymes have been studied in 7 small randomized trials with crossover designs, with mixed results. These studies had significant heterogeneity in patient selection, enzyme dosage and formulation, and outcome measures [14] . Octreotide has been studied in 4 randomized trials with mixed results and is rarely used. Although enzyme therapy may not provide substantial benefit, it is often tried because of its safety and the lack of other highly effective treatments.
The effects of antioxidants were tested in 2 relatively large randomized trials [15, 16] . Although serum levels of antioxidants increased in both trials, they produced different results for the outcome of pain relief. The trials included different types of patients; the trial with the positive results included much younger patients with mainly idiopathic pancreatitis, whereas the trial that produced negative results included older patients with alcohol and smoking as the primary etiologies [17] .
Antioxidants might reduce pain, but further studies are needed to define the patient population most likely to respond.
Patients with chronic pancreatitis should be educated about healthy lifestyle choices. They have increased risks of osteoporosis, osteopenia, and fractures [18] , so periodic assessments of bone density and vitamin D levels as well as routine dietary supplementation with vitamin D and calcium are recommended.
There is one form of chronic pancreatitis that has specific medical therapy.
Autoimmune pancreatitis occurs in 2 forms [19] . Type 1 is characterized by the presence of immunoglobulin G4-positive plasma cells in affected organs, and some patients have increased serum levels of immunoglobulin G4. Lithotripsy is necessary as an adjunct to endoscopic therapy for many patients with pancreatic duct stones. Interestingly, a randomized trial compared ESWL alone with ESWL followed by ERCP in removal of pancreatic duct stones [22] . Pain relief was equivalent between groups, and there were significant cost savings for the group that did not receive ERCP. These findings indicate that breaking up obstructing stones could be sufficient to improve ductal drainage and relieve pain. However, an alternative explanation is that lithotripsy reduces pain by a mechanism other than fracturing stones, perhaps by changing nociception through some effect on intrapancreatic nerves.
Another endoscopic treatment option is nerve block or neurolysis with EUS.
Neurolysis delivered by EUS guidance is safer and more effective than CT-guided techniques. EUS-guided delivery of bupivacaine and corticosteroids to block nerves has limited effectiveness in patients with chronic pancreatitis. Approximately 50% of patients have pain relief with a duration of a few weeks, so this approach is not Several surgical approaches involve drainage of the pancreatic duct along with localized resection of the pancreatic head, forms of a duodenum-preserving pancreatic head resection (DPPHR) or a pancreaticoduodenectomy (Whipple operation). These procedures are most frequently considered for patients with an inflammatory mass of the pancreatic head, often with associated obstruction of the bile duct or duodenum. Several randomized controlled trials reported a similar effect on pain following these operations but found that the Whipple procedure was more frequently associated with postoperative diabetes and lower quality of life [23, 24] .
There are 3 forms of DPPHR: the Frey, Beger, and Berne operations. These appear to be equally efficacious, and selection depends on local surgical expertise. Short-term pain relief from these operations appears equivalent to that from the modified Puestow operation. Long-term pain relief appears to be better [24] . Total pancreatectomy is also rarely performed and can be coupled with autotransplantation of islet cells. In this procedure, the resected pancreas is digested, and the islets are collected and infused into the portal vein; they implant in the liver and reduce the severity of diabetes after pancreatectomy. This operation has been considered a last resort for patients who have failed to respond to previous surgical therapies, although it is increasingly considered for patients who have not undergone surgery. Pain relief occurs in approximately 66% of patients after total pancreatectomy, indicating the complex extrapancreatic mechanisms of pain [25, 26] . A study reported that 45% of patients who underwent this procedure were initially insulin independent after surgery, although insulin independence decreased over time [25] . The risk of diabetes was inversely related to islet cell yield from the resected pancreas, and previous pancreatic drainage procedures (such as the modified Puestow operation) seemed to reduce yield. It is not clear whether this reduction in yield resulted from difficulties in digesting the pancreas to obtain islets following the modified Puestow operation or from the patients' stage of disease (more advanced disease with fewer residual surviving islets at the time of total pancreatectomy).
Patients must be carefully selected for total pancreatectomy with autotransplantation of islets so, for the moment, it is a last resort.
Two trials have compared endoscopic and surgical therapies for pain from chronic pancreatitis. The first included 72 patients treated with endoscopy (comprising sphincterotomy, stricture dilation and stenting, and stone extraction with lithotripsy if necessary) or surgery (simple drainage or DPPHR and Whipple operations) [27] . One year later, pain relief was equivalent between groups. After 5 years, 34% of the surgery group and 15% of the endoscopy group still had complete relief of pain. Partial relief of pain was equivalent between groups (approximately 50%).
A trial of 39 patients was stopped early because patients in the surgery group had significant improvements in outcome [28] . After a median follow-up period of 24 months, 75% of patients in the surgery group and 32% in the endoscopy group had complete or partial relief of pain. Five years later, 68% of patients in the endoscopy group underwent surgery, which remained superior in providing pain relief [29] .
Costs, quality of life, and pancreatic function were equivalent in the follow-up analysis.
These trials included patients with ductal anatomies that were amenable to endoscopic or surgical therapy. They primarily included patients with a dilated pancreatic duct and an obstructing stone or stricture. For these patients, surgery appears to be somewhat more effective and more durable than endoscopic therapy [30] . These results are appropriate to discuss with patients, many of whom will still opt for endoscopic therapy out of a desire to avoid surgery. The treatment of pain remains the most difficult challenge in managing patients with chronic pancreatitis [17] . Medical therapy is appropriate for all patients, and pain can be reduced to a manageable level in many. Endoscopy and surgery are options for select patients. An algorithm outlining a reasonable approach is presented (Fig. 3) .
Management of Exocrine Insufficiency
Exocrine insufficiency most commonly develops after 5 to 10 years of chronic pancreatitis but can also develop in patients with other pancreatic disorders There are quantitative methods to determine the efficacy of fat absorption, including a 72-hour fecal fat measurement and breath tests, but these are rarely performed outside of clinical research studies. Pancreatic enzyme therapy can be ineffective because of inadequate dose administration, asynchrony in delivery of enzymes and food simultaneously to the intestine (especially in patients who have undergone pancreatic surgery), or acid inactivation of lipase. Non-enteric-coated preparations require coadministration with acid-reducing agents, but these can also increase the efficacy of enteric-coated preparations. Acid-reducing agents allow enteric-coated enzymes to be released from their pH-sensitive delivery system more proximally in the duodenum, the site of most normal fat and fat-soluble vitamin absorption [31] . Continued failure of therapy despite an adequate dose and cotreatment with an H 2 -blocker or proton pump inhibitor usually indicates the presence of another cause of diarrhea or malabsorption; small intestinal bacterial overgrowth is the most common.
Management of Endocrine Insufficiency
Like exocrine insufficiency, endocrine insufficiency is typically a consequence of longstanding chronic pancreatitis. The relationship between diabetes and chronic pancreatitis is complex. Some patients with earlier stages of chronic pancreatitis have type 2 diabetes mellitus because of obesity and the metabolic syndrome. Some patients with long-term type 1 diabetes mellitus also develop chronic pancreatitis, but little is known about the mechanisms of this process.
Patients with long-term chronic pancreatitis or extensive pancreatic resection can develop type 3 diabetes mellitus [32] , characterized by a lack of insulin and other counter-regulatory islet hormones, such as glucagon. These features cause more frequent treatment-induced hypoglycemia and low levels of glucagon, pancreatic polypeptide, and gastric inhibitory peptide and, on rare occasions, ketoacidosis [32] .
Chronic pancreatitis is a risk factor for pancreatic cancer, and diabetes can increase this risk [33] . The use of an insulin-sensitizing agent such as metformin may reduce the risk of cancer in these patients. The exact prevalence of diabetes among patients with chronic pancreatitis is not known, but diabetes and impaired glucose tolerance are observed in many, depending on the stage of disease.
Diagnosis of diabetes in patients with pancreatitis relies on the same criteria as for all forms of diabetes: fasting plasma glucose level >126 mg/dL, 2-hour oral glucose tolerance test result >200 mg/dL, or hemoglobin A lc >6.5%. Although there are no screening and surveillance guidelines for chronic pancreatitis, it is reasonable to perform tests for fasting plasma levels of glucose and hemoglobin A lc , along with the standard glucose tolerance test, if findings are inconclusive. It is also reasonable to repeat these tests on a yearly basis.
Treatment of diabetes in patients with pancreatitis usually involves referral to an endocrine specialist. There are benefits to insulin therapy, but treatment-induced hypoglycemia is a potential disadvantage. Metformin may reduce the long-term risk of cancer but is often inadequate as a single agent to treat diabetes. Patients with low levels of insulin and C-peptide and low body mass would probably benefit most from insulin therapy but also have the highest risk of hypoglycemia.
Many additional complications can develop in patients with chronic pancreatitis, including osteoporosis, pancreatic pseudocyst formation, and pancreatic cancer. Although these are not discussed in detail, some aspects of management are outlined in Supplementary Table 3 .
Conclusion
The management of patients with chronic pancreatitis has undergone significant changes over the past decade. Strategies to increase the accuracy of diagnosis, better assess symptoms and complications, and manage patients using multidisciplinary teams have improved the care of these patients. Consistent delivery of the best evidence-based care has the potential to improve the health of many patients with chronic pancreatitis. Unfortunately, we still have many patients who remain symptomatic despite our best efforts. Connecting these patients with support groups, such as the National Pancreas Foundation (www.pancreasfoundation.org),
can increase the effects of treatment.
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